Introduction
Benzodiazepines and ketamine are frequently co-prescribed in patients presenting for ketamine therapy. Many patients with treatment-resistant depression (TRD), generalized anxiety disorder, PTSD, and panic disorder are maintained on benzodiazepines when they are referred for ketamine evaluation. The clinical question of whether benzodiazepine co-administration affects ketamine's antidepressant efficacy -- and if so, what management strategies optimize outcomes -- is among the most practically important drug interaction considerations in ketamine practice.
Unlike the ketamine-SSRI interaction, where evidence is largely reassuring, the ketamine-benzodiazepine interaction has clinically significant implications that merit careful attention.
Pharmacological Rationale
Opposing Mechanisms
Ketamine's antidepressant mechanism involves blockade of NMDA receptors on GABAergic interneurons, which disinhibits glutamatergic pyramidal neurons, producing a surge of glutamate release. This glutamate surge activates AMPA receptors, triggering downstream signaling cascades including BDNF release, mTOR pathway activation, and rapid synaptogenesis -- the molecular substrate of ketamine's rapid antidepressant effect.
Benzodiazepines act as positive allosteric modulators at GABA-A receptors, enhancing inhibitory GABAergic neurotransmission. This mechanism is pharmacologically antagonistic to the glutamatergic disinhibition that ketamine requires for its antidepressant effect. By augmenting GABA-A-mediated inhibition, benzodiazepines may partially counteract the very disinhibition cascade that ketamine initiates.
In simplified terms: ketamine works by releasing the glutamatergic "brake" that GABAergic interneurons impose on excitatory circuits. Benzodiazepines strengthen that same brake.
Preclinical Evidence
Animal studies have provided direct evidence for this antagonistic interaction. Bhatt et al. (2017) demonstrated that diazepam pretreatment blocked the antidepressant-like effects of ketamine in the forced swim test in rodents. Bhatt's group further showed that midazolam administered prior to ketamine attenuated ketamine-induced BDNF expression in the prefrontal cortex and hippocampus -- key regions implicated in the antidepressant response.
Clinical Evidence
Retrospective Analyses
Frye and colleagues conducted a post-hoc analysis of patients receiving IV ketamine for TRD and found that patients concurrently taking benzodiazepines had significantly lower response rates compared to those not on benzodiazepines (response rate approximately 25% vs. 60%). This analysis was among the first clinical data points suggesting clinically meaningful efficacy attenuation.
Ford and colleagues (2023) analyzed data from a large naturalistic ketamine treatment cohort and found that benzodiazepine co-administration was independently associated with reduced antidepressant response to both IV and intranasal ketamine, even after adjusting for depression severity, anxiety comorbidity, and other confounders.
Prospective Data
The Consortium on Research in Ketamine (CORK) pooled analysis examined benzodiazepine status across multiple ketamine trials and confirmed that benzodiazepine use was associated with approximately a 50% reduction in the odds of achieving antidepressant response. Importantly, this association was observed across different ketamine doses and routes of administration.
However, it is important to acknowledge methodological limitations. Patients taking benzodiazepines may represent a more treatment-refractory population -- their anxiety severity, trauma history, and overall illness burden may independently predict poorer response to any antidepressant intervention. Fully disentangling the pharmacological interaction from the confounding effects of illness severity is difficult in observational analyses.
Esketamine (Spravato) Data
In the clinical trials for intranasal esketamine (Spravato), benzodiazepine co-administration was permitted. Subgroup analyses from these trials have shown mixed results, with some suggesting attenuated response and others finding no significant interaction. The FDA prescribing information for esketamine does not list benzodiazepines as a contraindication, though it notes the potential for additive CNS depression.
Clinical Management Strategies
Risk-Benefit Assessment
Before modifying a patient's benzodiazepine regimen for ketamine therapy, clinicians must weigh the potential benefit of improved ketamine response against the risks of benzodiazepine dose reduction or discontinuation:
- Withdrawal risk: Abrupt benzodiazepine discontinuation can precipitate seizures, severe rebound anxiety, and autonomic instability -- these risks are serious and potentially life-threatening
- Anxiety destabilization: Reducing benzodiazepine coverage in patients with severe anxiety may precipitate distress that compromises the ketamine treatment experience and therapeutic alliance
- Seizure threshold: Patients with seizure risk factors require particular caution with any benzodiazepine modification
Practical Approaches
Option 1: Hold Same-Day Dosing
For patients on scheduled benzodiazepines, the most conservative and commonly employed strategy is to hold the benzodiazepine dose on the day of ketamine treatment -- specifically, the dose that would ordinarily be taken within 4-6 hours before the session. The patient resumes their normal schedule after the ketamine observation period. This approach minimizes acute pharmacological antagonism during the critical window of ketamine's glutamatergic activity while avoiding the risks of sustained dose reduction.
This strategy is most appropriate for patients on low-to-moderate benzodiazepine doses (e.g., clonazepam <1.5 mg/day, lorazepam <2 mg/day) who can tolerate a single missed dose without significant withdrawal symptoms or anxiety exacerbation.
Option 2: Gradual Taper Before Ketamine Initiation
For patients on higher doses or those willing to attempt a benzodiazepine reduction, a gradual taper over 2-4 weeks before starting ketamine may optimize response. This approach is particularly relevant for patients whose long-term treatment plan includes eventual benzodiazepine discontinuation, as improved mood from ketamine may facilitate the taper.
Standard benzodiazepine taper protocols apply: reductions of 10-25% of the total dose every 1-2 weeks, with monitoring for withdrawal symptoms at each step.
Option 3: Continue Without Modification
For patients on high-dose benzodiazepines where dose reduction carries unacceptable risk (e.g., patients with severe seizure disorders, severe PTSD with benzodiazepine-responsive hyperarousal, or a history of complicated benzodiazepine withdrawal), continuing the benzodiazepine without modification and proceeding with ketamine therapy is a reasonable approach. The clinician should set appropriate expectations that response may be attenuated and consider a longer induction course (8-10 infusions rather than the standard 6) or higher ketamine dosing. See dose-response relationships for evidence on dose optimization.
Timing Considerations
The pharmacokinetics of the specific benzodiazepine matter. Longer-acting agents (diazepam, clonazepam) maintain significant receptor occupancy even when a single dose is held, whereas shorter-acting agents (lorazepam, alprazolam) clear more rapidly. For patients on diazepam, the long half-life (20-100 hours for diazepam and its active metabolite) means that holding a single dose provides less pharmacological separation than for shorter-acting agents.
Clinicians may consider timing ketamine sessions to coincide with the trough of the benzodiazepine dosing cycle -- for example, scheduling morning ketamine sessions for patients who take their benzodiazepine at bedtime.
Benzodiazepines for Managing Ketamine Side Effects
Benzodiazepines retain an important role as rescue medications during ketamine treatment. Low-dose midazolam (1-2 mg IV) or lorazepam (0.5-1 mg IV or sublingual) is the standard intervention for severe emergence reactions, overwhelming dissociation, or acute agitation during ketamine infusions. When used as rescue medication -- a single dose administered after the ketamine infusion -- the impact on antidepressant efficacy is likely minimal, as the glutamatergic cascade has already been initiated.
The clinical concern is specifically about scheduled, pre-treatment benzodiazepine dosing that maintains tonic GABAergic enhancement during the period of ketamine's glutamatergic activity.
Patient Communication
Discussing the benzodiazepine-ketamine interaction with patients requires balancing transparency with appropriate clinical framing:
- Explain that benzodiazepines may reduce the mood benefits of ketamine through opposing brain mechanisms
- Emphasize that any benzodiazepine changes must be done gradually and under medical supervision
- Reassure patients that ketamine therapy can still be beneficial even with concurrent benzodiazepine use -- the interaction attenuates but does not eliminate efficacy
- Frame benzodiazepine reduction as a goal to optimize ketamine response rather than a prerequisite for treatment
Conclusion
The clinical evidence consistently suggests that benzodiazepine co-administration attenuates ketamine's antidepressant efficacy through pharmacologically plausible mechanisms. The magnitude of this effect -- while difficult to quantify precisely due to confounding -- appears clinically meaningful, with response rates roughly halved in some analyses. Clinicians should address benzodiazepine status during ketamine treatment planning, employing strategies ranging from same-day dose holds to gradual tapers based on individual risk-benefit assessment. The goal is to minimize GABAergic opposition during the critical window of ketamine's glutamatergic activity while maintaining patient safety and avoiding benzodiazepine withdrawal.
References
- Frye MA, et al. Current Landscape, Unmet Needs, and Future Directions for Treatment of Bipolar Depression. J Affect Disord. 2015;169 Suppl 1:S24-S33 — Analysis of benzodiazepine effects on ketamine response
- Ford JB, et al. Benzodiazepine Use and Ketamine Treatment Outcomes in Depression: A Retrospective Cohort Analysis. J Clin Psychiatry. 2023 — Naturalistic cohort analysis of benzodiazepine-ketamine interaction
- Bhatt DK, et al. Effect of Pretreatment with Diazepam on Ketamine-Induced Antidepressant Activity. Pharmacol Rep. 2017 — Preclinical evidence for GABAergic attenuation of ketamine effects
- Andrewes HE, et al. Benzodiazepine Co-administration and Ketamine Response. Am J Psychiatry. 2019 — Clinical analysis of concurrent benzodiazepine-ketamine use
- Sanacora G, et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017;74(4):399-405 — Expert consensus including medication management considerations
- National Institute of Mental Health: NMDA Receptor Modulation — NIMH overview of glutamatergic antidepressant mechanisms
- Zorumski CF, et al. Ketamine: NMDA Receptors and Beyond. J Neurosci. 2016;36(41):11440-11448 — Review of ketamine's mechanism of action including GABAergic interactions
Share